Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acne Infection01:27

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Hypersensitivities01:30

Hypersensitivities

Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis.

JCI insight·2025
Same author

Characteristics of youth utilizing pediatric dermatology: A cross-sectional PEDSnet study.

Journal of the American Academy of Dermatology·2025
Same author

Facial Rash Events in Dupilumab Phase 3 Atopic Dermatitis Trials: A Pooled Analysis.

Dermatitis : contact, atopic, occupational, drug·2025
Same author

Development and Validation of a Scale to Assess Epidermolysis Bullosa Simplex Severity.

JAMA dermatology·2025
Same author

Dupilumab Reduces Pruritus in Twins With Sjögren-Larsson Syndrome.

Pediatric dermatology·2025
Same author

Prevalence and Trends in Systemic Treatment for Pediatric Psoriasis in the USA between 2015 and 2021.

Dermatology and therapy·2025

Related Experiment Video

Updated: May 23, 2026

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

Latest approaches to treating atopic dermatitis.

Amy S Paller1

  • 1Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Ill., USA.

Chemical Immunology and Allergy
|March 22, 2012
PubMed
Summary

Atopic dermatitis (AD) treatment requires addressing skin barrier defects, immune issues, and environmental factors. Therapies include moisturizers, dilute bleach baths for some children, and topical or systemic medications, with newer biologics on the horizon.

More Related Videos

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Related Experiment Videos

Last Updated: May 23, 2026

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Area of Science:

  • Dermatology
  • Immunology
  • Genetics

Background:

  • Atopic dermatitis (AD) arises from a complex interplay of epidermal barrier dysfunction, immune system dysregulation, and environmental influences.
  • Understanding these contributing factors is crucial for effective patient management.
  • Current therapeutic strategies aim to address these multifaceted aspects of the condition.

Purpose of the Study:

  • To review current understanding of atopic dermatitis (AD) pathogenesis.
  • To discuss current and emerging therapeutic strategies for AD.
  • To highlight the importance of a comprehensive approach to managing AD.

Main Methods:

  • Literature review of recent investigations into AD.
  • Analysis of current treatment modalities for AD.
  • Discussion of emerging therapies including biologics.

Main Results:

  • AD involves epidermal barrier defects, immune dysfunction, and environmental triggers.
  • Moisturizers are essential for barrier repair.
  • Dilute bleach baths can benefit children with moderate-to-severe AD, particularly those with staphylococcal infections.
  • Oral vitamin D(3) is being investigated for its potential role in enhancing antimicrobial peptides.
  • Topical corticosteroids and calcineurin inhibitors remain primary treatments with a generally good safety profile.
  • Systemic immunosuppressants and biologics are options for severe AD.
  • Patient compliance and distinguishing AD from contact dermatitis are critical for treatment success.

Conclusions:

  • Effective atopic dermatitis (AD) management necessitates a multi-pronged approach targeting skin barrier, immune response, and environmental factors.
  • Standard therapies like moisturizers and topical agents are foundational.
  • Emerging treatments, including biologics, hold promise for revolutionizing severe AD therapy.